Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04182763 · ClinicalTrials.gov registry record · NA
CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)
A NA study of Pantothenate Kinase-Associated Neurodegeneration, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 77
- Enrollment target
- 1
- Study location
NCT04182763: Completed NA study of Pantothenate Kinase-Associated Neurodegeneration, sponsored by Oregon Health and Science University.
NCT04182763 is a NA study of Pantothenate Kinase-Associated Neurodegeneration that has completed, run by Oregon Health and Science University. The registered enrollment target is 77 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04182763, a NA study of Pantothenate Kinase-Associated Neurodegeneration, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about how people with the condition pantothenate kinase-associated neurodegeneration (PKAN) respond to a specialized study product. We are hoping to find out if the study product is safe, what effects-good and bad-the study product causes, and whether the study product changes certain measures of disease in PKAN.
Primary Outcome
Safety will be measured using the number of treatment-emergent adverse events (both AE and SAE) by treatment arm. Counts are adjusted for number of prescription medications at baseline as a measure of baseline disease severity.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER CoA-Z
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2025-01-01 |
| Phase | NA |
What the finished NCT04182763 record still lists
NCT04182763 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Pantothenate Kinase-Associated Neurodegeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04182763 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT04182763 about?
NCT04182763 is a clinical study titled "CoA-Z in Pantothenate Kinase-associated Neurodegeneration (PKAN)". The purpose of this study is to learn more about how people with the condition pantothenate kinase-associated neurodegeneration (PKAN) respond to a specialized study product. We are hoping to find out if the study product is safe, what effects-good and bad-the study product causes, and whether the s...
What is the current status of trial NCT04182763?
This trial is currently completed. It is a NA study. The enrollment target is 77 participants. The study started on 2019-12-04. Estimated completion is 2025-01-01.
What conditions does trial NCT04182763 study?
This clinical trial studies the following conditions: Pantothenate Kinase-Associated Neurodegeneration.
What interventions are being tested in trial NCT04182763?
The interventions under investigation include: Placebo (OTHER), CoA-Z (OTHER).
Who is sponsoring clinical trial NCT04182763?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04182763 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04182763's enrollment target sits among peer trials
77 1062nd of 2000 higher than 939 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI